1. Home
  2. ARMP vs CEV Comparison

ARMP vs CEV Comparison

Compare ARMP & CEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARMP
  • CEV
  • Stock Information
  • Founded
  • ARMP N/A
  • CEV 1999
  • Country
  • ARMP United States
  • CEV United States
  • Employees
  • ARMP N/A
  • CEV N/A
  • Industry
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • CEV Finance/Investors Services
  • Sector
  • ARMP Health Care
  • CEV Finance
  • Exchange
  • ARMP Nasdaq
  • CEV Nasdaq
  • Market Cap
  • ARMP 80.0M
  • CEV 71.3M
  • IPO Year
  • ARMP N/A
  • CEV N/A
  • Fundamental
  • Price
  • ARMP $2.06
  • CEV $10.06
  • Analyst Decision
  • ARMP Strong Buy
  • CEV
  • Analyst Count
  • ARMP 1
  • CEV 0
  • Target Price
  • ARMP $7.00
  • CEV N/A
  • AVG Volume (30 Days)
  • ARMP 13.8K
  • CEV 19.6K
  • Earning Date
  • ARMP 11-13-2024
  • CEV 01-01-0001
  • Dividend Yield
  • ARMP N/A
  • CEV 4.23%
  • EPS Growth
  • ARMP N/A
  • CEV N/A
  • EPS
  • ARMP N/A
  • CEV 0.36
  • Revenue
  • ARMP $5,467,000.00
  • CEV N/A
  • Revenue This Year
  • ARMP $23.87
  • CEV N/A
  • Revenue Next Year
  • ARMP N/A
  • CEV N/A
  • P/E Ratio
  • ARMP N/A
  • CEV $29.36
  • Revenue Growth
  • ARMP 34.92
  • CEV N/A
  • 52 Week Low
  • ARMP $1.80
  • CEV $8.83
  • 52 Week High
  • ARMP $4.48
  • CEV $10.91
  • Technical
  • Relative Strength Index (RSI)
  • ARMP 49.88
  • CEV 41.39
  • Support Level
  • ARMP $1.97
  • CEV $9.91
  • Resistance Level
  • ARMP $2.28
  • CEV $10.23
  • Average True Range (ATR)
  • ARMP 0.14
  • CEV 0.06
  • MACD
  • ARMP 0.01
  • CEV 0.01
  • Stochastic Oscillator
  • ARMP 54.17
  • CEV 46.88

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest

Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.

Share on Social Networks: